Using anti-GITR monoclonal antibodies, Cohen et al. demonstrated that GITR agonism led to lower intratumoral Treg accumulation, loss of FoxP3 expression, decreased Treg suppressor function, and, ultimately, regression of B16 melanoma in mouse models [150]. This evidence concerns the gene TNFRSF18 and melanoma.